Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

← catalyst calendar

NCT04229979

Sponsored by Sellas Life Sciences Group (industry) · SLS — their whole pipeline →. With PPD Development, LP.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

127actual

Sites

Countries

France, Germany, Greece +7

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2021-02-08

actual

When the study began enrolling

Primary completion

Dec 2025

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2026

estimated

The whole study's end, after follow-up

First posted

2020-01-18

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-10-01

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Acute Myeloid Leukemia

Interventions

Biological: Galinpepimut-S — also filed as SLS-001, GPS
Drug: Azacitidine
Drug: Venetoclax
Drug: Decitabine
Drug: Cytarabine — also filed as Ara-C
Other: Observation
Biological: GM-CSF — also filed as sargramostim
Other: Montanide

Primary outcome

what the primary-completion date above is the date OF

measured 5 years

Publications

PMID 39606837 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · SLS's whole pipeline · Catalyst calendar · Every registered study · What changed